1) Incorporate newer GBS prognostic tools in clinical practice, and understand how they are impacting drug trial design
2) Understand the current state of clinimetrics in CIDP both for clinical practice and drug trials, vis a vis the concept of minimum clinically important difference (MCID)
3) Recognize the unmet needs and challenges in anti-MAG neuropathy drug development
4) Appreciate the role of natural history studies in defining metrics for successful autoimmune neuropathy outcome for patients.